NIMOTOP Drug Patent Profile

When do Nimotop patents expire, and what generic alternatives are available?

Nimotop is a drug marketed by Bayer Pharms and is included in one NDA.

The generic ingredient in NIMOTOP is nimodipine. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nimodipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nimotop

A generic version of NIMOTOP was approved as nimodipine by HERITAGE on May 2^nd, 2007.

Summary for NIMOTOP

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	125
Clinical Trials:	9
Patent Applications:	5,331
DailyMed Link:	NIMOTOP at DailyMed

Recent Clinical Trials for NIMOTOP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	Early Phase 1
Medical University of Vienna	Phase 2
Rijnstate Hospital	Phase 2

See all NIMOTOP clinical trials

US Patents and Regulatory Information for NIMOTOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988		DISCN	Yes	No

Expired US Patents for NIMOTOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988

International Patents for NIMOTOP

See the table below for patents covering NIMOTOP around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	22818
Finland	791162
Sweden	447248	ANVENDNING AV 1,4-DIHYDRO-2,6-DIMETYL-4-(3-NITROFENYL)-PYRIDIN-3-BETA-METOXI-ETYLESTER-5-ISOPROPYLESTER FOR FRAMSTELLNING AV CEREBRALT VERKSAMMA LEKEMEDEL

NIMOTOP Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Nimotop

Introduction to Nimotop

Nimotop, the brand name for the prescription drug Nimodipine, is a 2nd generation dihydropyridine calcium channel blocker. It is primarily used for the prevention and treatment of cerebral vasospasm following an aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke with high mortality and morbidity rates[4][5].

Market Size and Growth Projections

The Nimodipine market, which includes Nimotop, is experiencing significant growth. As of 2023, the market size was valued at USD 100 billion and is projected to reach USD 147.4 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5% from 2024 to 2031[3].

Key Drivers of Market Growth

Several factors are driving the growth of the Nimodipine market:

Aging Population and Increasing Incidence of aSAH

The global cerebral vasospasm market, closely related to Nimodipine, is expected to grow at a CAGR of +6.5%, driven by an aging population that is at higher risk of experiencing aSAH and vasospasm. The increasing number of reported aSAH cases worldwide is expanding the potential patient pool for vasospasm treatment[1].

Lifestyle Behaviors and Healthcare Focus

Lifestyle behaviors and the increasing focus of healthcare systems on sophisticated therapies for cerebrovascular disorders are also contributing to market growth. The rising prevalence of stroke and the need for efficient post-hemorrhagic complication management are key drivers[3].

Clinical Trials and Novel Formulations

Ongoing clinical trials investigating novel therapeutic applications and improved formulations of Nimodipine are enhancing its market appeal. The development of new medicine delivery methods and the focus on enhancing patient care in critical situations further support market expansion[3].

Acquisition and Its Impact

LXO Group's Acquisition of Nimotop

Laboratoire X.O (LXO), backed by Stanley Capital Partners, has acquired Nimotop from Bayer for several markets globally, excluding mainland China. This acquisition marks a significant milestone in LXO's history and is part of a broader strategy to consolidate and integrate established medicines with high barriers to entry[2][4][5].

Strategic Benefits

The acquisition strengthens LXO's market presence in Europe and significantly expands its global footprint. Nimotop adds to LXO’s core therapeutic areas for the Central Nervous System and Cardiovascular, creating synergies and diversifying its global portfolio. This move is expected to enable an uplift of LXO’s valuation multiple[2][4].

Late Lifecycle Management Strategy

LXO has identified Nimotop as a strong candidate to deploy its proven late lifecycle management skills. This strategy includes:

Digital Marketing

Enlarging the serviceable available market (SAM) through digital marketing to reach a broader audience and increase market penetration[2][4].

Geographic Expansion

Pursuing geographic expansion to make Nimotop available in more countries and regions, leveraging LXO's distribution network in over 80 countries[2][4].

Optimising Market Access

Optimising market access to ensure that the treatment is accessible to patients in more than 45 countries, maintaining and developing access to this life-saving drug[2][4].

Financial Trajectory

Organic and External Growth

The acquisition of Nimotop is expected to provide a strong basis for further accelerated growth through both organic and external opportunities. LXO's management is committed to making the most of this opportunity for patients, employees, and shareholders[2][4].

Valuation Multiple Uplift

The diversification of LXO’s global portfolio and the addition of Nimotop are expected to enable an uplift of its valuation multiple, reflecting the increased value and potential of the company[2][4].

Industry Expert Insights

Patrick Hargutt, Founding Partner at Stanley Capital Partners, noted that Stanley Capital is actively working with LXO’s management team to further strengthen and support the company through its next phase of growth. The acquisition of Nimotop follows a highly impressive M&A track record and a clear strategy to pursue further bolt-ons from their actively curated pipeline in established medicines[2][4].

Simon Cottle, Founding Partner at Stanley Capital Partners, added that the acquisition represents a further milestone in diversifying LXO’s product portfolio and will accelerate the internationalisation of the business. The increased scale secured builds on their work to create systematic and digitised life cycle management systems[2][4].

Conclusion

The acquisition of Nimotop by LXO, backed by Stanley Capital Partners, marks a significant step in the company's growth strategy. With a strong market growth trajectory driven by demographic changes, increasing incidence of aSAH, and ongoing clinical innovations, Nimotop is poised to play a critical role in LXO's expansion and financial success.

Key Takeaways

• Market Growth: The Nimodipine market is projected to grow from USD 100 billion in 2023 to USD 147.4 billion by 2031 at a CAGR of 5%.
• Key Drivers: Aging population, increasing incidence of aSAH, lifestyle behaviors, and ongoing clinical trials drive market growth.
• Acquisition Impact: The acquisition strengthens LXO's market presence and global footprint, adding to its core therapeutic areas.
• Late Lifecycle Management: LXO will deploy its proven late lifecycle management skills, including digital marketing, geographic expansion, and market access optimization.
• Financial Trajectory: The acquisition is expected to drive organic and external growth, leading to an uplift in LXO’s valuation multiple.

FAQs

Q: What is Nimotop used for? A: Nimotop is used for the prevention and treatment of cerebral vasospasm following an aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke[4].

Q: Who acquired Nimotop from Bayer? A: Laboratoire X.O (LXO), backed by Stanley Capital Partners, acquired Nimotop from Bayer for several markets globally, excluding mainland China[2][4][5].

Q: What is the projected market size of Nimodipine by 2031? A: The Nimodipine market is expected to reach USD 147.4 billion by 2031, growing at a CAGR of 5% from 2024 to 2031[3].

Q: How does LXO plan to manage Nimotop post-acquisition? A: LXO plans to deploy its proven late lifecycle management skills, including enlarging the serviceable available market through digital marketing, pursuing geographic expansion, and optimizing market access[2][4].

Q: What is the impact of the acquisition on LXO’s valuation? A: The acquisition is expected to enable an uplift of LXO’s valuation multiple due to the diversification of its global portfolio and the addition of Nimotop[2][4].

Sources

1. LXO Group Announces the Acquisition of Prescription Drug Nimotop from Bayer - LXO Group Press Release, November 6, 2023.
2. Stanley Capital-Backed LXO Acquires Nimotop From Bayer - Pharmaceutical Manufacturer, November 6, 2023.
3. Nimodipine Market Size By Product, By Application, By Geography - Market Research Intellect, December 2024.
4. Stanley Capital-backed LXO acquires Nimotop® from Bayer - Stanley Capital Partners, November 6, 2023.
5. Stanley Capital-backed LXO acquires Nimotop® from Bayer - PharmiWeb, November 6, 2023.